JP2023531919A5 - - Google Patents
Info
- Publication number
- JP2023531919A5 JP2023531919A5 JP2022578616A JP2022578616A JP2023531919A5 JP 2023531919 A5 JP2023531919 A5 JP 2023531919A5 JP 2022578616 A JP2022578616 A JP 2022578616A JP 2022578616 A JP2022578616 A JP 2022578616A JP 2023531919 A5 JP2023531919 A5 JP 2023531919A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- weeks
- patient
- form according
- administered daily
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063043681P | 2020-06-24 | 2020-06-24 | |
| US63/043,681 | 2020-06-24 | ||
| PCT/US2021/038789 WO2021262914A1 (en) | 2020-06-24 | 2021-06-24 | Compositions and methods for treating obsessive-compulsive disorder |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023531919A JP2023531919A (ja) | 2023-07-26 |
| JP2023531919A5 true JP2023531919A5 (cg-RX-API-DMAC7.html) | 2024-06-28 |
| JP7805969B2 JP7805969B2 (ja) | 2026-01-26 |
Family
ID=79281806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022578616A Active JP7805969B2 (ja) | 2020-06-24 | 2021-06-24 | 強迫性障害を治療するための組成物及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230181541A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4171554A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7805969B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230027189A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115968312A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021297249A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022025901A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3187323A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL299301A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022016174A (cg-RX-API-DMAC7.html) |
| PH (1) | PH12022553441A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021262914A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP2400349A1 (hu) * | 2024-07-05 | 2026-01-28 | Egis Gyógyszergyár Zrt. | Troriluzole-hidroklorid-sók |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2819303T3 (es) | 2005-04-05 | 2021-04-15 | Univ Yale | Agentes moduladores del glutamato en el tratamiento de trastornos mentales |
| DK3265448T3 (da) | 2015-03-03 | 2022-03-28 | Biohaven Therapeutics Ltd | Riluzol-prodrugs og anvendelse deraf |
| DK3297619T3 (da) | 2015-05-22 | 2022-08-15 | Vistagen Therapeutics Inc | Terapeutiske anvendelser af L-4-chlorkynurenin |
| US10751345B2 (en) | 2018-02-21 | 2020-08-25 | AI Therapeutics, Inc. | Combination therapy with apilimod and glutamatergic agents |
| CN112203692A (zh) | 2018-05-27 | 2021-01-08 | 拜尔哈文制药股份有限公司 | 利鲁唑口腔崩解片用于治疗疾病的用途 |
| JP2021530543A (ja) | 2018-07-22 | 2021-11-11 | バイオヘイブン・セラピューティクス・リミテッドBiohaven Therapeutics Ltd. | アルツハイマー病を処置するためのリルゾールプロドラッグの使用 |
| CN112584831A (zh) | 2018-08-16 | 2021-03-30 | 拜奥海芬治疗学有限公司 | 利鲁唑口腔崩解片用于治疗疾病的用途 |
-
2021
- 2021-06-24 IL IL299301A patent/IL299301A/en unknown
- 2021-06-24 MX MX2022016174A patent/MX2022016174A/es unknown
- 2021-06-24 BR BR112022025901A patent/BR112022025901A2/pt unknown
- 2021-06-24 KR KR1020237001813A patent/KR20230027189A/ko active Pending
- 2021-06-24 PH PH1/2022/553441A patent/PH12022553441A1/en unknown
- 2021-06-24 AU AU2021297249A patent/AU2021297249A1/en active Pending
- 2021-06-24 EP EP21829058.3A patent/EP4171554A4/en active Pending
- 2021-06-24 CA CA3187323A patent/CA3187323A1/en active Pending
- 2021-06-24 US US17/923,587 patent/US20230181541A1/en active Pending
- 2021-06-24 JP JP2022578616A patent/JP7805969B2/ja active Active
- 2021-06-24 CN CN202180044180.1A patent/CN115968312A/zh active Pending
- 2021-06-24 WO PCT/US2021/038789 patent/WO2021262914A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2435041B1 (en) | Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent | |
| CA2529742A1 (en) | Composition of a vegf antagonist and an anti-proliferative agent | |
| JP2017529382A5 (cg-RX-API-DMAC7.html) | ||
| WO2006029036A3 (en) | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis | |
| Younis et al. | CGRP receptor antagonists (gepants) | |
| JP2021530543A5 (cg-RX-API-DMAC7.html) | ||
| WO2009104149A1 (en) | Combination comprising paclitaxel for treating ovarian cancer | |
| KR20050085681A (ko) | 프로테아제 억제제와 같은 사이토크롬 p450의 억제제와함께 비-뉴클레오시드 역전사효소 억제제(nnrti)를함유하는 배합물의 용도 | |
| JP2005525409A5 (cg-RX-API-DMAC7.html) | ||
| JP2025517509A5 (cg-RX-API-DMAC7.html) | ||
| KR20050075012A (ko) | 항암제에 의해 유발된 말초신경증의 예방 및/또는 치료를위한 아세틸-l-카르니틴 | |
| WO2018132791A1 (en) | Treatment of neurodegenerative conditions by disruption of rhes | |
| US20240207199A1 (en) | Fluorocarbon compositions and methods for enhancing immunotherapy | |
| JP2024518426A5 (cg-RX-API-DMAC7.html) | ||
| US20210386736A1 (en) | Combination therapy for treating cancer | |
| HUP0202120A2 (hu) | Daganatellenes kombináció | |
| Sims-McCallum | Triple antifungal therapy for the treatment of invasive aspergillosis in a neutropenic pediatric patient. | |
| CN112533605A (zh) | 用于治疗癌症的组合疗法 | |
| Kim et al. | Weekly low dose paclitaxel and cisplatin as first-line chemotherapy for advanced non-small cell lung cancer | |
| JP6243850B2 (ja) | 抗がん剤による末梢神経障害の予防、治療、または軽減剤 | |
| HK40040830A (en) | Combination therapy for treating cancer | |
| Keady et al. | Caspofungin in the treatment of invasive fungal infections | |
| US20240122916A1 (en) | Effect of YEL002 on Conditions and Diseases | |
| HK40040825A (zh) | 用於治疗癌症的组合疗法 | |
| EP4153180A1 (en) | Combination therapy for treating cancer |